134 related articles for article (PubMed ID: 30925541)
1. Massive Periocular Squamous Cell Carcinoma With Response to Pembrolizumab (Keytruda).
Conger JR; Grob SR; Tao J
Ophthalmic Plast Reconstr Surg; 2019; 35(5):e127. PubMed ID: 30925541
[No Abstract] [Full Text] [Related]
2. Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma.
Degache E; Crochet J; Simon N; Tardieu M; Trabelsi S; Moncourier M; Templier I; Foroni L; Lemoigne A; Pinel N; Gil H; Bouillet L; Leccia MT; Charles J
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e257-e258. PubMed ID: 28557105
[No Abstract] [Full Text] [Related]
3. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
[No Abstract] [Full Text] [Related]
4. Immunotherapy in Squamous Cell Skin Carcinoma: A Game Changer?
Ravulapati S; Leung C; Poddar N; Tu Y
Am J Med; 2017 May; 130(5):e207-e208. PubMed ID: 28249663
[No Abstract] [Full Text] [Related]
5. GQ1b-Seronegative Miller Fisher Syndrome Associated With Pembrolizumab.
Green KE; Levine AM; Ward JH; Kaufman DI
J Neuroophthalmol; 2019 Sep; 39(3):394-396. PubMed ID: 30801443
[No Abstract] [Full Text] [Related]
6. Clinical Response With Pembrolizumab for Cutaneous Squamous Cell Carcinoma.
Corbett M; Tohani S; Ramli R; O'Duffy F
JAMA Otolaryngol Head Neck Surg; 2024 Jun; 150(6):524-525. PubMed ID: 38602669
[TBL] [Abstract][Full Text] [Related]
7. Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation.
Ali SA; Arman HE; Patel AA; Birhiray RE
JCO Oncol Pract; 2020 Mar; 16(3):137-138. PubMed ID: 31770056
[No Abstract] [Full Text] [Related]
8. In brief: Pembrolizumab (Keytruda) for cancers with biomarkers.
Med Lett Drugs Ther; 2018 Jan; 60(1537):e8. PubMed ID: 29294466
[No Abstract] [Full Text] [Related]
9. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
Venkatesh S; Al-Haseni A; Sahni D
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab as first line treatment of Merkel cell carcinoma patients - a case series of patients with various co-morbidities.
Bystrup Boyles T; Schødt M; Hendel HW; Krarup-Hansen A; Junker N
Acta Oncol; 2020 Jul; 59(7):793-796. PubMed ID: 32285728
[No Abstract] [Full Text] [Related]
11. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer.
Winkler JK; Schneiderbauer R; Bender C; Sedlaczek O; Fröhling S; Penzel R; Enk A; Hassel JC
Br J Dermatol; 2017 Feb; 176(2):498-502. PubMed ID: 27061826
[No Abstract] [Full Text] [Related]
12. Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab.
Jang S; Venna S
J Oncol Pract; 2017 Jul; 13(7):462-464. PubMed ID: 28562196
[No Abstract] [Full Text] [Related]
13. Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab.
Thiem A; Kneitz H; Schummer P; Herz S; Schrama D; Houben R; Goebeler M; Schilling B; Gesierich A
Acta Derm Venereol; 2017 Nov; 97(10):1252-1254. PubMed ID: 28761962
[No Abstract] [Full Text] [Related]
14. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
Tran DC; Colevas AD; Chang AL
JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
[No Abstract] [Full Text] [Related]
15. RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma.
Morgado-Carrasco D; Bosch-Amate X; Fustà-Novell X; Giavedoni P
Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):161-163. PubMed ID: 31874704
[No Abstract] [Full Text] [Related]
16. Complete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive Therapy.
Sadaat M; Jang S
J Oncol Pract; 2018 Mar; 14(3):198-199. PubMed ID: 29257718
[No Abstract] [Full Text] [Related]
17. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
[No Abstract] [Full Text] [Related]
18. Case Report of Multiple Keratoacanthomas and Squamous Cell Carcinomas in a Patient Receiving Pembrolizumab.
Chaudhari S; Leon A; Levin E; Neuhaus I; Liao W
J Drugs Dermatol; 2017 May; 16(5):513-515. PubMed ID: 28628690
[TBL] [Abstract][Full Text] [Related]
19. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.
Borradori L; Sutton B; Shayesteh P; Daniels GA
Br J Dermatol; 2016 Dec; 175(6):1382-1386. PubMed ID: 27059424
[No Abstract] [Full Text] [Related]
20. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
[No Abstract] [Full Text] [Related]
[Next] [New Search]